Edoxudine
 |
| ATC code |
|
| Legal status |
- In general: ℞ (Prescription only)
|
5-ethyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
|
| CAS Number |
|
|
PubChem CID
|
|
| ChemSpider |
|
| UNII |
|
| ChEMBL |
|
|
CompTox Dashboard (EPA)
|
|
| ECHA InfoCard |
100.035.645
|
| Formula |
C11H16N2O5
|
| Molar mass |
256.25514 g·mol−1
|
| 3D model (JSmol) |
|
O=C/1NC(=O)N(\C=C\1CC)[C@@H]2O[C@@H]([C@@H](O)C2)CO
|
InChI=1S/C11H16N2O5/c1-2-6-4-13(11(17)12-10(6)16)9-3-7(15)8(5-14)18-9/h4,7-9,14-15H,2-3,5H2,1H3,(H,12,16,17)/t7-,8+,9+/m0/s1 N
Key:XACKNLSZYYIACO-DJLDLDEBSA-N N
|
N Y (what is this?) (verify)
|
Edoxudine (or edoxudin) is an antiviral drug. It is an analog of thymidine, a nucleoside.
It has shown effectiveness against herpes simplex virus.
Synthesis
Edoxudine synthesis: Synthesis via organopalladium intermediates:
Mercuration of the 2'-deoxyuridine 1 leads to the organometallic derivative 2; reaction of that with ethylene in the presence dilithiopalladium tetrachloride gives the alkylation product 3; this is reduced catalytically in situ. There is thus obtained the antiviral agent edoxudine 4.